Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02758990
Other study ID # 001
Secondary ID
Status Terminated
Phase N/A
First received April 26, 2016
Last updated September 27, 2017
Start date March 2016
Est. completion date November 23, 2016

Study information

Verified date October 2016
Source Verifomics LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.


Description:

The study is composed of multiple interventions which will last between 2 and 6 months that evaluate a suite of predictions about the way that a given environmental factor impacts a specific health outcome based on genetic information obtained from direct-to-consumer genotyping providers (AncestryDNA and 23andMe). Substances of interest include foods, nutritional supplements and non-invasive medical devices.

A minimum of 500 subjects will be enrolled in each intervention, and only those subjects which are predicted to benefit from the intervention when considering all sites of interest will be assigned to an intervention. The predictions are based on hundreds to thousands of sites of interest at high minor allele frequency single nucleotide polymorphisms and predictions about response are derived from the aggregate genotype at all loci considered. As such each site of interest will have a built-in negative control group composed of individuals enrolled in the intervention despite a genotype at that site that does not predict a benefit. The rate that each site of interest makes correct predictions about subject response will be compared to randomly-selected sites in order to quantify placebo effects and establish quality metrics for the predictions.

Enrollment and participation are conducted remotely. Participants will upload genetic information from a direct-to-consumer provider through a mobile or web browser application, and informed consent and inclusion/exclusion criteria are accomplished remotely. After the informed consent process, participants are asked what phenotype of interest (weight, migraines, insomnia, etc.) they are interested in studying, their genetic information is evaluated and they are allowed to select an intervention they qualify for based on their genetics that they would like to participate in. Participants then answer a series of questions to establish baseline data on relevant factors as well as evaluate the inclusion and exclusion criteria; participants that qualify for the intervention are then given specific instructions on how to participate, and may then use the software to report data during the intervention. Each intervention utilizes a specific product rather than a general class of product to reduce noise from differing sourcing, distribution, storage and manufacturing practices.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date November 23, 2016
Est. primary completion date November 23, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- For BMI interventions, BMI > 25

- For headache interventions, more than 2 headache-days per month

- For insomnia interventions, at least one day of self-reported poor sleep per week

- For rhinitis interventions, more than 2 days with symptoms per month

- For joint pain interventions, at least one day of self-reported joint pain per week

Exclusion Criteria:

- Women who are pregnant, nursing or attempting to become pregnant

- Immediately life-threatening disease

- Current use of nutritional supplements of interest (excluded from those interventions to prevent overdose)

- For spinach interventions, gout

Study Design


Intervention

Dietary Supplement:
Vitamin A
Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
Vitamin B6
Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
Vitamin C
Subjects will be asked to increase vitamin C intake by 500 mg per day.
Nicotinamide
Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
Vitamin D3
Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
Vitamin E
Subjects will be asked to increase vitamin E intake by 400 International Units per day.
Other:
Broccoli
Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
Spinach
Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
Dietary Supplement:
Caffeine
Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
Other:
Coffee
Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
Device:
Axon Eyewear
Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
Other:
Chocolate
Subjects will be asked to increase chocolate intake by eating 57g per day.

Locations

Country Name City State
United States Verifomics, LLC Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Verifomics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of correct predictions Each site of interest is being evaluated for its ability to make correct predictions about subject response. This frequency will be compared via a variety of statistical techniques to that expected by chance to establish its clinical utility. Assessed 30 days after enrollment, comparing values of phenotypes of interest in the final week of the intervention to the value at enrollment and determining if the actual response is consistent with the prediction made prior to enrollment
Secondary Genotype-independent effects of substances of interest Baseline responses to environmental factors studied in terms of phenotypes of interest are measured to remove this potential bias from the analysis of predictive power. Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in body mass index Assessed 30 days after enrollment, comparing value at enrollment to value after 30 days of participation
Secondary Change in headache severity Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in headache frequency Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in rhinitis severity Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in rhinitis frequency Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in insomnia frequency Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in insomnia severity Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in joint pain severity Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary Change in joint pain frequency Assessed 30 days after enrollment, comparing value at enrollment to value after in the final week of participation
Secondary "Question of the day" questionnaire Asynchronous longitudinal observations about subject health, diet, environment, lifestyle and anecdotal observations to be used to guide future studies, control for co-linear changes in behavior, monitor for serendipitous events and assess environment-environment interactions. Subjects are asked to answer one question from the survey per day, and questions are asked recurrently at question-specific intervals. Daily for the duration of participation (2 to 6 months), starting on the day of enrollment and ending when the intervention is concluded, either because the scientific endpoints are met or the subjects voluntarily halt participation..
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2